PEPTIDE DATABASE

Retatrutide

LY3437943

An investigational peptide-based triple receptor agonist targeting GIP, GLP-1 and glucagon receptors, studied primarily in metabolic and obesity-related clinical research.

Triple GIP / GLP-1 / glucagon receptor agonist Clinical-stage investigational compound Investigational; regulatory status depends on jurisdiction and indication
COMPOUND DATA

Molecular Information

Classification Triple GIP / GLP-1 / glucagon receptor agonist
Molecular Weight Not available
Molecular Formula Not available
Research Status Clinical-stage investigational compound
BIOLOGICAL ATLAS

Systems Associated With Retatrutide

Brain & CNS

Human Clinical
Clinical research association

Triple GIP, GLP-1 and glucagon receptor agonist investigated in metabolic clinical research.

Gastrointestinal

Human Clinical
Clinical research association

Triple GIP, GLP-1 and glucagon receptor agonist investigated in metabolic clinical research.

Liver

Human Clinical
Clinical research association

Triple GIP, GLP-1 and glucagon receptor agonist investigated in metabolic clinical research.

Pancreas & Glucose

Human Clinical
Clinical research association

Triple GIP, GLP-1 and glucagon receptor agonist investigated in metabolic clinical research.

Metabolic

Human Clinical
Clinical research association

Triple GIP, GLP-1 and glucagon receptor agonist investigated in metabolic clinical research.

Adipose Tissue

Human Clinical
Clinical research association

Triple GIP, GLP-1 and glucagon receptor agonist investigated in metabolic clinical research.

Endocrine & Hormonal

Human Clinical
Clinical research association

Triple GIP, GLP-1 and glucagon receptor agonist investigated in metabolic clinical research.

STATUS

Regulatory Information

Investigational; regulatory status depends on jurisdiction and indication

Regulatory status can vary by jurisdiction and may change over time.

HaxBio provides information for educational and research purposes. Information on this page should not be interpreted as medical advice.